Counterfeit Ozempic drugs sold abroad: Delhi court junks anticipatory bail plea of man involved in racket
The man, Vicky Ramancha, is accused of orchestrating an international criminal conspiracy to supply counterfeit drugs to foreign entities.
Additional Sessions Judge Saurabh Pratap Singh Laler of Patiala House Court noted in his order, 'Swift legal action against pharmaceutical crimes is essential for maintaining India's position as the 'Pharmacy of the World' and protecting legitimate manufacturers from regulatory backlash.'
'India's pharmaceutical industry represents a strategic national asset requiring protection from criminal exploitation. The supply of counterfeit pharmaceuticals represents a direct threat to public health and safety,' he added.
As per the Economic Offences Wing which is investigating the crime, the 'sophisticated transnational fraud operation' allegedly caused financial losses close to 19 million US dollars to Assure Global LLC, which was the complainant in this case.
'Economic consequences (of such an offence) include loss of market share for legitimate manufacturers, reduction in export revenues and foreign exchange earnings, increased regulatory compliance costs for entire industry, and potential trade sanctions and import restrictions by recipient countries,' the court said.
'The regulatory and diplomatic impact involves damage to India's reputation as a reliable pharmaceutical manufacturer, increased scrutiny from international regulatory bodies (FDA, EMA, WHO), potential disruption of pharmaceutical trade agreements, and strain on diplomatic relationships with importing nations,' it added.
The prosecution outlined that there were broader implications of such a crime, including public health and safety concerns.
It also stated that the international nature of the alleged crimes created concerns about destruction of electronic records and communications, influencing international co-conspirators and manipulation of complex financial records across jurisdictions.
The accused had argued over territorial jurisdiction, stating that no part of the alleged criminal conspiracy occurred within Indian territory.
It was the contention of the defence counsel that all agreements were executed outside India and the pharmaceutical products were delivered from China to the USA. The lawyer also stated that the complainant in this case was a foreign entity.
To which the judge said, 'The applicant allegedly used Indian legal systems to lend legitimacy to fraudulent operations through notarisation of key documents at Patiala House Courts, creation of false impression of government backing through use of official Indian legal processes.'
'Modern criminal law recognises that transnational crimes cannot escape prosecution merely because they span multiple jurisdictions. The principle of territoriality must be applied pragmatically in cases involving international fraud schemes,' he added, dismissing the defence counsel's argument.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
5 minutes ago
- Time of India
Is Novo Nordisk facing its 'Nokia moment'? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forces
Novo Nordisk's stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal challenges fuel concerns over the Danish drugmaker's grip on the global diabetes and obesity market. Novo Nordisk, Denmark's pharma powerhouse, has seen its stock plunge from record highs as fierce competition, slowing growth, and market shifts test its dominance in the global diabetes and obesity drug market. Tired of too many ads? Remove Ads Intensifying Competitive Pressures Compounded versions from U.S. pharmacies —driven by FDA shortages—have eaten into branded sales. —driven by FDA shortages—have eaten into branded sales. Eli Lilly's Zepbound and Mounjaro are gaining prescription share. As of July 2025, Zepbound holds 59% of prescriptions compared to Wegovy's 40%, signaling a material shift in market preference. Tired of too many ads? Remove Ads Leadership Transition Amid Turbulence Legal and Regulatory Headwinds Analysts Split: Crash or Correction? Novo Nordisk: Denmark's global pharma giant Tired of too many ads? Remove Ads Key Innovative Advances Bolster Long-Term Outlook Amycretin – Dual-Action Obesity Drug: Phase 1b/2a trials show 22% average body weight loss over 36 weeks, sparking a ~12% stock bump. CagriSema – Record Weight Loss in Phase III: Achieved 20.4% weight reduction in obese adults and 13.7% in type 2 diabetes patients. Oral Semaglutide & Amycretin: Oral formulations are under U.S. regulatory review, potentially broadening adoption. $2.2B Septerna Partnership: Four programs targeting obesity, type 2 diabetes, and cardiometabolic diseases. Insulin Icodec (Awiqli) – Once-Weekly Insulin: Approved in Canada, EU, and Japan, improving patient adherence. NNC2215 – Glucose-Sensitive 'Smart' Insulin: Adjusts activity based on blood sugar, reducing hypoglycemia risk. Alhemo (Concizumab) – Hemophilia Treatment: FDA-approved July 2025 for A and B types. AI and Rare Disease Expansion: Collaborations with Heartseed, Ventus Therapeutics, and megaTAL platform targeting cardiovascular, MASH, and CKD therapies. So, Is This a 'Nokia Moment'? Summary Snapshot Indicator Status Sales & Profit Guidance Significantly lowered; investor reaction strongly negative Competition & Market Threats Rising; compounded drugs and Eli Lilly products erode share Leadership & Strategy New CEO; strategic clarity still evolving Legal & Regulatory Risks Class-action lawsuit; compounding disputes add uncertainty Valuation & Sentiment Deeply discounted; mix of caution and opportunistic value Long-term Outlook Not terminal; pipeline and global expansion offer growth levers Investor Takeaways Defensive stance: Exercise caution until guidance execution and competitive dynamics are clearer. Exercise caution until guidance execution and competitive dynamics are clearer. Value opportunity: Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Contrarian investors may view the sharp dip as a long-term buying chance, particularly if Novo can regain share and deliver on pipeline milestones. Catalysts to watch: CEO performance, legal outcomes, regulatory action on compounding, and international R&D breakthroughs. FAQs: Novo Nordisk (NYSE: NVO) closed at $50.39 on Thursday, down $0.51 (-1%), extending its staggering decline from a year-high of $139.74. Investors are questioning whether the Danish pharmaceutical giant is approaching its own 'Nokia moment'—a pivotal inflection point where market dominance is challenged by nimble competitors and shifting industry Novo Nordisk lowered itsfrom. Operating profit (EBIT) growth was also trimmed to. The announcement triggered a, wiping out roughlyInvestors had expected continued dominance in the lucrative obesity and diabetes markets, but the downgrade sent an unmistakable warning: growth is slowing, and the competitive landscape is shifting Nordisk's blockbuster drugsandhave faced growing headwinds:These trends highlight a: traditional competition and unregulated compounding pharmacies undermining pricing CEOstepped down on, passing the reins to. The new CEO faces immediate challenges: stabilizing sales, defending market share, and restoring investor watchers emphasize that leadership changes at such a sensitive moment can either signal a bold strategic pivot or deepen uncertainty, depending on how quickly Doustdar asserts his Nordisk is also navigating U.S. legal scrutiny. A class-action lawsuit claims the company misled investors about competitive risks and overstated growth institutions are taking note: UBS downgraded NVO to 'neutral' and cut its target price from 600 to 340 Danish kroner, warning that competitive and compounding pressures are 'here to stay.'Market opinion is divided. Some analysts foresee additional downside, while others highlight support near $47.50 as a potential stabilization point. Contributors on Seeking Alpha argue that the sell-off may have priced in worst-case scenarios, leaving room for a measured recovery if Novo's R&D pipeline delivers next-generation weight-loss drugs or accelerates global Nordisk started its journey in Denmark in the 1920s, when two small companies—Nordisk and Novo—were founded to make insulin for people with diabetes. In 1989, the two merged to form Novo Nordisk as we know it today. The company's largest owner is the Novo Nordisk Foundation, which holds nearly a third of the shares but controls more than three-quarters of the voting in Bagsværd, just outside Copenhagen, Novo Nordisk has grown into one of the world's most valuable pharmaceutical companies. In mid-2025, it's worth around, although last year it briefly touched almost, putting it among the most valuable companies on the home, its impact is hard to overstate. Novo Nordisk is Denmark's biggest taxpayer, a major exporter, and an economic powerhouse—at one point its market value was larger than Denmark's entire GDP. Today, it's not just a national success story but a global leader in diabetes, obesity, and rare disease short-term headwinds, Novo Nordisk is pursuing multiple growth avenues:These developments suggest Novo's, providing potential long-term exactly. While Novo Nordisk faces heightened competition, slowing growth, leadership changes, and legal pressures, it retains robust cash flows, a dominant market footprint, and a promising turbulence is clear. Yet a full-scale Nokia-style collapse is unlikely given Novo's strategic assets and global reach. The company is navigating a near-term storm, but its innovation engine and expansion efforts leave the door open for Nordisk is at a critical crossroads. The company isn't collapsing, but it's clear that the weight-loss and diabetes markets are no longer uncontested territory. How the company navigates competition, regulation, and innovation in the coming months will determine whether this is a temporary stumble—or the start of a deeper stock fell after 2025 sales guidance cuts and rising competition from Eli Lilly drugs and compounded drugs and pharmacy compounding have reduced market share and investor confidence.
The Hindu
5 minutes ago
- The Hindu
India ‘fully engaged' with U.S. on trade deal, says Commerce Secretary
India continues to be 'fully engaged' with the U.S. on a Bilateral Trade Agreement, Commerce Secretary Sunil Barthwal said on Thursday, however adding that the date for the next round of negotiations has not yet been decided. He reiterated the deadline for the deal as fall 2025, or September-October 2025, as announced by Prime Minister Narendra Modi and U.S. President Donald Trump. Official sources have also confirmed that India was working with both the U.K. and the EU to fast-track the implementation of the respective trade deals India was concluding with them. During the Indian team's visit to Washington in July to continue negotiations on the deal, it had been decided that the next round would take place in New Delhi during the last week of August. However, a lot has changed since then. US President Donald Trump on July 31 approved a 25% tariff on imports from India, and then on August 6 approved an additional 25% tariffs as a 'penalty' for India's imports of Russian oil. Mr. Trump has also indicated that further negotiations would not take place until the Russia oil issue was resolved. Against this backdrop of uncertainty, Mr. Barthwal said that negotiations on the BTA were still progressing. Negotiations progressing 'We are fully engaged with the U.S. on the trade negotiations,' Mr. Barthwal said at a press briefing. 'There was a joint statement that was given by the U.S. President and our Prime Minister where it was said India and the U.S. would engage in a bilateral trade agreement and simultaneously we would also aim to more than double our trade to $500 billion.' 'Those talks are going on,' he added. 'The BTA talks are going on. We are engaged.' However, Mr. Barthwal added that the final date for the next round of negotiations would be decided closer to the last week of August. According to official sources who declined to be named, the negotiations and engagement between India and the U.S. was taking place at different levels. 'One level is at the negotiating team' level, another one happens at the Ministers' level, the third happens at the diplomatic levels, and we also engage the different industries of the U.S. to look into their issues,' the official explained. Other deals being fast-tracked The India-United Kingdom Comprehensive Economic and Trade Agreement (CETA), signed in July, is now in the final stage where the UK is concluding its due processes in its Parliament. 'We have requested the UK to fast-track this process so it comes into force as early as possible,' another government source said. They added that the Trade and Economic Partnership Agreement (TEPA) between India and the EFTA countries — Iceland, Liechtenstein, Norway and Switzerland — would come into force on October 1. 'With the EU, we are fast-tracking the negotiations,' they explained. 'But a lot of work has progressed and it was decided that the FTA would be concluded by the end of December. It has made good progress and there are further meetings that are going to happen, at the negotiators' level, the Secretary level, and at the Ministerial level.' With Oman, the talks on a trade agreement have concluded and the deal will be signed 'very soon', when the dates are decided by both countries. Good progress with ASEAN countries The negotiating team representing the Association of Southeast Asian Nations (ASEAN) countries was in India between August 10-14 to review the Trade in Goods Agreement between the two. 'We are telling them that we need to increase trade between India and ASEAN,' the official said. 'Everybody is concerned about the uncertain global policy environment. They have realised that both ASEAN and India move forward and improve trade between the two blocks.' They added that India and the ASEAN countries were not only looking at tariff issues but also non-tariff issues, such as Sanitary and Phytosanitary (SPS) measures and Technical Barriers to Trade (TBT) and regulatory compliances. 'Since these are issues that require deep analysis, that analysis is going on,' the official said. 'This round has been quite fruitful. There is a lot of clarity on how we should move forward.'
Mint
5 minutes ago
- Mint
‘Four strategy pillars': India working to fast-track FTAs amid higher US tariffs, says Commerce Secretary
Commerce Secretary Sunil Barthwal on August 14 said that the government is working on 'four strategy pillars', including fast-tracking of free trade agreements (FTAs) with the UK and European Union to improve export competitiveness amid higher US tariffs on Indian exports, PTI reported. The other pillars are promoting ease of doing business, export diversification (products and markets), and import diversification, Barthwal said. According to Barthwal, India has requested the UK to fast-track approval of the Comprehensive Economic and Trade Agreement (CETA), which was signed on July 24, so that it comes into force as early as possible. He told reporters that negotiations with the EU have also been fast-tracked, adding, 'A lot of work has progressed in the proposed pact between India and the EU, and both sides are hoping to conclude the talks by the end of this year. There are further meetings that are going to happen on this at the negotiator, secretary and minister's level.' Meanwhile, talks with Oman have concluded, and the deal may be signed when dates are decided mutually by both countries, he said. 'That (trade pact with Oman) is very close in terms of signing,' the secretary said. Further, discussions are also progressing with New Zealand, Peru, and Chile. While review negotiations regarding an FTA in goods with the 10-nation Asean bloc is also happening. 'Yesterday we discussed how we can improve trade between India and ASEAN. We are also focussing on increasing FTA utilisation with countries with which we have already signed these pacts,' he said. Bathwal noted that working on a strategy is crucial for India amid the steep tariffs imposed by the US — Donald Trump's tariffs have climbed to a total combined 50 per cent on Indian imports into America. The decision is likely to impact key sectors such as chemicals, leather and footwear, gems and jewellery and textiles. 'There are uncertainties because of these are getting is still no clarity about what is happening on the globe. In this uncertain environment, we thought that let's have a clear-cut strategy so that we can focus on our exports in a manner which is within our have strategised across four pillars,' Barthwal said. Under strengthening export promotion, the ministry already has different export promotion schemes, but there is a need to further strengthen them. In import diversification, there is a need to reduce dependencies on a few countries and enhance domestic sales. "First approach is to focus on our free trade agreements (FTAs)," he said, adding the commerce ministry will work on fast tracking facilitating the utilisation of these pacts. "We are looking at saturation of FTA is a gradual process, but we will be focusing now more on this," he said. The ministry, he said, is now focusing on 30 more countries in addition to 20 earlier, for pushing India's exports. These 50 countries constitute more than 90 per cent of India's export basket, and they include Malaysia, Indonesia, Mexico, Italy, Belgium, Nigeria, Oman and Poland. "As a strategy, we will focus on these countries. We will do more export promotion activities in these nations," Barthwal said. On the impact of US tariffs on India, an official said the ministry is in touch with stakeholders. 'We know the sectors that are more exposed towards the are talking to export promotion councils and trying to understand their exposure to the US,' the official said, adding states are also looking at how they help and facilitate exports. The official said trade in domestic currencies may also be discussed during meetings between a visiting high-level Indian delegation and Russian counterparts. "A very high-level delegation is going from MEA (Ministry of External Affairs), and the commerce will also be participating in that high-level delegation to Russia," the official said.
